Heartland Bank & Trust Co Purchases Shares of 2,284 DaVita Inc. $DVA

Heartland Bank & Trust Co acquired a new position in shares of DaVita Inc. (NYSE:DVA) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,284 shares of the company’s stock, valued at approximately $351,000.

Several other hedge funds also recently modified their holdings of DVA. Root Financial Partners LLC boosted its stake in DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Elevation Wealth Partners LLC increased its stake in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares in the last quarter. Caitlin John LLC acquired a new position in shares of DaVita during the fourth quarter valued at about $34,000. Sankala Group LLC acquired a new position in shares of DaVita during the fourth quarter valued at about $39,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of DaVita during the 2nd quarter worth about $43,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on DVA shares. Barclays boosted their target price on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. TD Cowen boosted their price objective on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. UBS Group upped their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Truist Financial increased their target price on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and an average price target of $216.50.

DaVita Price Performance

NYSE:DVA opened at $236.93 on Friday. DaVita Inc. has a one year low of $101.00 and a one year high of $239.64. The company has a market cap of $15.21 billion, a PE ratio of 21.98, a PEG ratio of 0.78 and a beta of 0.88. The firm has a 50-day moving average of $209.94 and a 200-day moving average of $164.49.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts expect that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.90% of the stock is owned by company insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.